Bionano Bought the Reimbursement Ticket; It Didn't Buy a Higher Number
A MolDX coverage proposal across 31 states, two CPT codes and a Sloan Kettering launch — and still a reiterated $31–33 million year with a 2027 'vision' standing in for a framework.
BNGO · Earnings Call · 2026-11-10
The paperwork cleared. The guidance didn't move.
Bionano spent the third quarter collecting exactly the artifacts a structural-variant testing company needs in order to get paid: in late August MolDX published a proposed local coverage determination for OGM-based detection of copy number alterations and structural variants in hematologic neoplasms, spanning Medicare contractor jurisdictions covering 31 states and roughly 61% of the U.S. population; the AMA's two Category 1 CPT codes now have CMS-established rates behind them; and New York State approved OGM laboratory-developed tests at University of Rochester Medicine and Memorial Sloan Kettering. The keyword record reads like a receipt: Medicare coverage is the company's number-one keyword this quarter, Coverage determination is third, State approval eighth, and MolDX one of the sharpest risers in the whole series. Then management repeated itself. “Revenue for the third quarter of 2026 was $8.3 million, up 12% compared to Q3 2025.” — Mark Adamchak · 2026-11-10 Full-year guidance stayed at $31–33 million — growth of 9% to 16% — and Mark Adamchak pointed to the midpoint. Alongside that sat a genuinely good operating datapoint: 9,870 nanochannel array flow cells sold, up 18% and a record for any quarter, on top of consumable revenue of $4.7 million (+24%) and other revenue of $2.5 million (+24%). Here is the tension. The last filed quarter — the one behind the descriptor data — had revenue of roughly $8 million, up 21% year over year. Q3 came in at +12%. Record units, decelerating dollars. Part of the bridge is software, which fell 31% to $1.1 million, and part is the accounting of reagent rentals, where flow cells shipped do not convert one-for-one into recognized revenue. Ludwig acknowledged the direction of travel on software revenue: “As we begin to see the transition of array via customers to OGM, we will eventually recognize some decline in software revenue” — Albert Luderer · 2026-11-10 — a cannibalization the company is choosing, but a margin-mix headwind nonetheless.Where a framework used to be, there is now a vision
The most revealing moment came on the first question. An analyst asked whether the September investor-conference framework of $50–54 million of 2027 revenue with roughly breakeven adjusted EBITDA exiting Q4 still governed the operating plan. The answer reframed it from plan to aspiration:That is a $50–54 million target — roughly 1.6x the top of this year's guidance — being gently demoted. It also sits at odds with the trajectory of the language itself. Two quarters ago the company's number-one keyword was cash flow breakeven, and in May the answer on that subject was flat: “No, we do not expect to reach cash flow breakeven by the end of 2026.” — Mark Adamchak, Vice President of Accounting and Principal Accounting Officer · 2026-05-13 This quarter, breakeven does not appear in the top thirty keywords at all. It has been replaced by reimbursement vocabulary — a company that has stopped talking about survival math and started talking about coverage math. Which makes the cash line the thing to stare at. Bionano ended Q3 with $8.7 million in cash, cash equivalents and available-for-sale securities, $0.5 million of it restricted, against free cash flow of about -$6 million in the last filed quarter. The gross-margin story is genuinely better — gross margin has climbed from the low 20s in 2023 to the high 40s, with Q3 adjusted gross margin at 48% versus 46%, and adjusted operating expense down 9% to $8.8 million. But a company burning mid-single-digit millions per quarter with under $9 million of liquidity is running a reimbursement-driven race against a balance sheet.In September, when I spoke at the Wainwright conference, I presented a vision of what we might be in the future. And I want this to be a guideline for where this company and its underlying technology can be and what it can do as it transforms medicine.
The constraint that will not go away
Supply has now been the explanation for three consecutive calls. In August:In November the language was identical in substance — “there's a long lead time for some of our most critical components and notably the silicon wafer that has all the nano channels” — Albert Luderer · 2026-11-10 — with a plan to roughly double capacity mid-next-year and to be clear of back orders by the end of this year. A supply constraint that caps the top end of guidance is a reasonable excuse once; by the third repetition it is a structural feature of the model, and note that the capacity doubling lands in mid-2027, the year it is supposed to serve. What has not fallen off is the underlying demand logic. Management still credits the same engine it always has: “the very strong clinical evidence that's global in nature, backed up by the CPT coding and now MolDX is favorable determination for hematologic oncology” — Albert Luderer · 2026-11-10. That was the same claim in August, when the growth was attributed to “existing clients” — Albert A. Luderer, Chairman and Interim CEO · 2026-08-10 — the routine use base, not new placements. This quarter's evidence base grew: MD Anderson's 332-sample MDS study, Oulu's 48 cytogenetically normal AML samples, Josep Carreras' therapy-related cohort, and 365 papers year-to-date.we are very much constrained in terms of our flow cell manufacturing capacity... we are in back order.